MARKET

ATRS

ATRS

Antares Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.250
-0.060
-1.81%
Pre Market: 3.250 0 0.00% 08:22 01/27 EST
OPEN
3.320
PREV CLOSE
3.310
HIGH
3.370
LOW
3.182
VOLUME
150
TURNOVER
--
52 WEEK HIGH
5.07
52 WEEK LOW
3.110
MARKET CAP
552.64M
P/E (TTM)
8.64
1D
5D
1M
3M
1Y
5Y
FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity
The 
Benzinga · 01/18 17:39
Antares Pharma's ATRS-1902 gets US FDA fast track status for adrenal crisis rescue
Antares Pharma's (ATRS -2.4%) hydrocortisone rescue pen ATRS-1902 received the U.S. Food and Drug Administration's fast track designation for adrenal crisis rescue. The company said the development program for ATRS-1902 supports
Seekingalpha · 01/18 17:20
BRIEF-Antares Pharma Receives FDA Fast Track Designation For ATRS-1902 For Adrenal Crisis Rescue
reuters.com · 01/18 12:34
Antares Pharma, Inc.'s (NASDAQ:ATRS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Most readers would already be aware that Antares Pharma's (NASDAQ:ATRS) stock increased significantly by 11% over the...
Simply Wall St. · 01/13 09:46
BRIEF-Antares Pharma Appoints Claude Richardson As Senior Vice President Of Human Resources
reuters.com · 01/12 13:54
Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human Resources
EWING, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, announced today the appointment of Claude E. Richardson as Senior Vice President of Human Resources. Mr. Richardson will...
GlobeNewswire · 01/12 13:30
Antares Pharma reports positive results from Phase I ATRS-1902 study for adrenal crisis
Antares Pharma (NASDAQ:ATRS) announces positive results from a Phase I study for ATRS-1902 for adrenal crisis. Acute adrenal crisis is a life-threatening state caused by insufficient levels of cortisol, which
Seekingalpha · 01/11 14:04
Antares Pharma Announces Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue; Co. Reports 'The results of the Phase I cross-over study met its primary objective showing ATRS-1902 delivered a comparable pharmacokinetic profile to Solu-Cortef'
Antares Pharma, Inc. (NASDAQ:ATRS) (the “Company”), a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis.
Benzinga · 01/11 12:34
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATRS. Analyze the recent business situations of Antares Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ATRS stock price target is 6.33 with a high estimate of 7.00 and a low estimate of 5.00.
High7.00
Average6.33
Low5.00
Current 3.250
EPS
Actual
Estimate
0.010.020.030.04
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 234
Institutional Holdings: 93.36M
% Owned: 54.90%
Shares Outstanding: 170.04M
TypeInstitutionsShares
Increased
69
4.37M
New
21
1.87M
Decreased
42
4.20M
Sold Out
19
1.41M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.33%
Healthcare Equipment & Supplies
-1.22%
Key Executives
Chairman/Independent Director
Leonard Jacob
President/Chief Executive Officer/Director
Robert Apple
Chief Financial Officer/Executive Vice President
Fred Powell
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Peter Graham
Executive Vice President
Peter Richardson
Director
Carmen Volkart
Independent Director
Thomas Garrity
Independent Director
Peter Greenleaf
Independent Director
Anton Gueth
Independent Director
Robert Roche
Independent Director
Karen Smith
No Data
About ATRS
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products and technologies. The Company develops, manufactures, and commercialize, for itself or with partners, therapeutic products using its drug delivery systems. The Company products include XYOSTED, NOCDURNA, Epinephrine Injection USP, Sumatriptan Injection USP, Makena and Teriparatide Injection. Its XYOSTED injection product for subcutaneous administration of testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency or absence of endogenous testosterone. NOCDURNA is used for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per night to urinate. Its Epinephrine Injection USP products is indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and certain pediatric patients.

Webull offers kinds of Antares Pharma Inc stock information, including NASDAQ:ATRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRS stock methods without spending real money on the virtual paper trading platform.